Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nokia Corp (NOK) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Nokia CorpTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Nokia Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.42 (market cap $8.04B), while Nokia Corp trades at $11.39 (market cap $65.32B). The key difference: Nokia Corp is far larger — about 8.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Nokia Corp pays a 1.4% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIONOK
Market Cap
$8.04B$65.32B
Sector
HealthTechnology
52-Week High
$339.75$16.83
52-Week Low
$241.71$4.05
Enterprise Value
$7.85B$62.14B
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

Nokia Corp

Nokia (NOK) trades at $11.675, down 6.04% today amid a broader technical pullback despite strong AI-driven momentum. The stock has surged over 100% YTD on AI infrastructure partnerships, including a $1 billion deal with Nvidia. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beat estimates. Valuation metrics appear elevated with a P/E of 73.32, while profitability remains modest with a 3.98% net margin. Cash flow trends show volatility, with 2025 net cash flow negative at -$1.16 billion.

Nokia's AI transformation presents significant upside potential with analyst consensus target of $18.00 (54% upside), but high valuation and execution risks warrant caution. The company's pivot to AI networking infrastructure is gaining traction, though supply constraints and heavy R&D spending could pressure near-term profitability. Technical indicators suggest near-term bearish pressure with key support at $11.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK